PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 14619570-1 2003 OBJECTIVE: To explore the effects of arsenic trioxide (As2O3) on tissue factor (TF), plasminogen activator inhibitor-1(PAI-I) and PAI-2 expression in NB4, HL-60 and THP-1 cells. Arsenic Trioxide 37-53 coagulation factor III, tissue factor Homo sapiens 65-78 14619570-8 2003 The TF antigen levels were down-regulated during the As2O3-induced apoptosis of NB4 cells (P < 0.01), and the down-regulation effect of TF antigen levels was in the As2O3-concentration dependent fashion. Arsenic Trioxide 53-58 coagulation factor III, tissue factor Homo sapiens 4-6 14619570-8 2003 The TF antigen levels were down-regulated during the As2O3-induced apoptosis of NB4 cells (P < 0.01), and the down-regulation effect of TF antigen levels was in the As2O3-concentration dependent fashion. Arsenic Trioxide 168-173 coagulation factor III, tissue factor Homo sapiens 139-141 14619570-11 2003 The TF antigen levels were up-regulated and the PAI-2 antigen levels were down-regulated during the As2O3-induced apoptosis of HL-60 cells (P < 0.01 and P < 0.05, TF and PAI-2 respectively). Arsenic Trioxide 100-105 coagulation factor III, tissue factor Homo sapiens 4-6 14619570-11 2003 The TF antigen levels were up-regulated and the PAI-2 antigen levels were down-regulated during the As2O3-induced apoptosis of HL-60 cells (P < 0.01 and P < 0.05, TF and PAI-2 respectively). Arsenic Trioxide 100-105 coagulation factor III, tissue factor Homo sapiens 169-171 14619570-13 2003 The TF and PAI-2 antigen levels in THP-1 cells were up-regulated after the exposure to 8 mumol/L As2O3 for 24 h (P < 0.05 and P < 0.01, TF and PAI-2 respectively). Arsenic Trioxide 97-102 coagulation factor III, tissue factor Homo sapiens 4-6 14619570-13 2003 The TF and PAI-2 antigen levels in THP-1 cells were up-regulated after the exposure to 8 mumol/L As2O3 for 24 h (P < 0.05 and P < 0.01, TF and PAI-2 respectively). Arsenic Trioxide 97-102 coagulation factor III, tissue factor Homo sapiens 142-144 14619570-14 2003 CONCLUSION: The effects of As2O3 on TF, PAI-1 and PAI-2 antigen levels in NB4, HL-60 and THP-1 cells are distinct. Arsenic Trioxide 27-32 coagulation factor III, tissue factor Homo sapiens 36-38 14619570-1 2003 OBJECTIVE: To explore the effects of arsenic trioxide (As2O3) on tissue factor (TF), plasminogen activator inhibitor-1(PAI-I) and PAI-2 expression in NB4, HL-60 and THP-1 cells. Arsenic Trioxide 55-60 coagulation factor III, tissue factor Homo sapiens 65-78 14619570-1 2003 OBJECTIVE: To explore the effects of arsenic trioxide (As2O3) on tissue factor (TF), plasminogen activator inhibitor-1(PAI-I) and PAI-2 expression in NB4, HL-60 and THP-1 cells. Arsenic Trioxide 55-60 coagulation factor III, tissue factor Homo sapiens 80-82 16206674-7 2001 Abnormal high expression of TF in APL cell was downregulated in patients treated with ATRA or As2O3. Arsenic Trioxide 94-99 coagulation factor III, tissue factor Homo sapiens 28-30 11779431-11 2001 The down-regulating effect of ATRA and As2O3 on TF expression in U937 cells might not involve this fusion protein. Arsenic Trioxide 39-44 coagulation factor III, tissue factor Homo sapiens 48-50 11369412-1 2001 To study the in vivo effect of all-trans-retinoic acid (ATRA) and arsenic trioxide (As(2)O(3)) on the expression of tissue factor (TF) and the other hemostatic disturbance, a series of parameters were measured either in bone marrow blasts or plasma from acute promyelocytic leukemia (APL) patients. Arsenic Trioxide 66-82 coagulation factor III, tissue factor Homo sapiens 116-129 11369412-1 2001 To study the in vivo effect of all-trans-retinoic acid (ATRA) and arsenic trioxide (As(2)O(3)) on the expression of tissue factor (TF) and the other hemostatic disturbance, a series of parameters were measured either in bone marrow blasts or plasma from acute promyelocytic leukemia (APL) patients. Arsenic Trioxide 66-82 coagulation factor III, tissue factor Homo sapiens 131-133 11779431-0 2001 Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells. Arsenic Trioxide 38-54 coagulation factor III, tissue factor Homo sapiens 58-71 11779431-1 2001 OBJECTIVE: To study the effect of all-trans retinoic acid (ATRA) and arsenic troxide (As2O3) on tissue factor (TF) expression and procoagulant activity (PCA) of acute promyelocytic leukemia (APL) cells in vivo and in vitro. Arsenic Trioxide 86-91 coagulation factor III, tissue factor Homo sapiens 96-109 11779431-1 2001 OBJECTIVE: To study the effect of all-trans retinoic acid (ATRA) and arsenic troxide (As2O3) on tissue factor (TF) expression and procoagulant activity (PCA) of acute promyelocytic leukemia (APL) cells in vivo and in vitro. Arsenic Trioxide 86-91 coagulation factor III, tissue factor Homo sapiens 111-113 11779431-5 2001 RESULTS: Both ATRA and As2O3 can down-regulate the TF antigen, its mRNA transcription and membrane PCA of APL cells in vivo and in vitro, in a time-dependent manner. Arsenic Trioxide 23-28 coagulation factor III, tissue factor Homo sapiens 51-53 11779431-7 2001 Both ATRA and As2O3 can also down-regulate the TF antigen in U937 cells transfected with or without PML-RARa. Arsenic Trioxide 14-19 coagulation factor III, tissue factor Homo sapiens 47-49 11779431-8 2001 CONCLUSION: Tissue factor expression and PCA in APL cells may be down-regulated by ATRA and As2O3. Arsenic Trioxide 92-97 coagulation factor III, tissue factor Homo sapiens 12-25 11779431-9 2001 By down-regulating TF expression, As2O3 might also be used to improve the DIC-related hemorrhage in APL. Arsenic Trioxide 34-39 coagulation factor III, tissue factor Homo sapiens 19-21 10400422-3 1999 Notably, clinical improvement was also correlated to ATRA/As2O3-induced rapid decrease of membrane procoagulant activity (PCA) and TF contents of APL blasts. Arsenic Trioxide 58-63 coagulation factor III, tissue factor Homo sapiens 131-133 11798557-1 2001 OBJECTIVES: To study the changes of tissue factor expression and hemostatic molecular markers in acute promyelocytic leukemia during all-trans retinoic acid (ATRA) or arsenic trioxide (AS(2)O(3)) treatment. Arsenic Trioxide 167-183 coagulation factor III, tissue factor Homo sapiens 36-49 11798557-7 2001 All-trans retinoic acid and arsenic trioxide down-regulate the expression of TF mRNA and decrease the TF contents in APL blasts. Arsenic Trioxide 28-44 coagulation factor III, tissue factor Homo sapiens 77-79 11798557-7 2001 All-trans retinoic acid and arsenic trioxide down-regulate the expression of TF mRNA and decrease the TF contents in APL blasts. Arsenic Trioxide 28-44 coagulation factor III, tissue factor Homo sapiens 102-104 11876987-0 2000 [Mechanism of tissue factor expression on NB4 cells down-regulated by all-trans retinoic acid and arsenic trioxide]. Arsenic Trioxide 98-114 coagulation factor III, tissue factor Homo sapiens 14-27 11876987-1 2000 OBJECTIVE: To investigate molecular mechanism of tissue factor (TF) expression on acute promyelocytic leukemia cell line NB4 cells down-regulated by all-trans retinoic acid (ATRA) and arsenic trioxide (As(2)O(3)). Arsenic Trioxide 184-200 coagulation factor III, tissue factor Homo sapiens 49-62 11876987-1 2000 OBJECTIVE: To investigate molecular mechanism of tissue factor (TF) expression on acute promyelocytic leukemia cell line NB4 cells down-regulated by all-trans retinoic acid (ATRA) and arsenic trioxide (As(2)O(3)). Arsenic Trioxide 184-200 coagulation factor III, tissue factor Homo sapiens 64-66 11798779-0 2000 [Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells]. Arsenic Trioxide 40-56 coagulation factor III, tissue factor Homo sapiens 60-73 11798779-1 2000 OBJECTIVE: To investigate the effects of all-trans retinoic acid (ATRA) and arsenic trioxide (As(2)O(3)) on both tissue factor (TF) expression and procoagulant activity (PCA) of acute promyelocytic leukemia (APL) cells in vivo and in vitro. Arsenic Trioxide 76-92 coagulation factor III, tissue factor Homo sapiens 113-126 11775254-1 2000 OBJECTIVE: To study in vivo effect of all-trans-retinoic acid (ATRA) or arsenic trioxide (As2O3) on the expression of tissue factor (TF) and the hemostatic disorders, a series of parameters were measured in bone marrow blasts and plasma from acute promyelocytic leukemia (APL) patients. Arsenic Trioxide 72-88 coagulation factor III, tissue factor Homo sapiens 118-131 11775254-1 2000 OBJECTIVE: To study in vivo effect of all-trans-retinoic acid (ATRA) or arsenic trioxide (As2O3) on the expression of tissue factor (TF) and the hemostatic disorders, a series of parameters were measured in bone marrow blasts and plasma from acute promyelocytic leukemia (APL) patients. Arsenic Trioxide 72-88 coagulation factor III, tissue factor Homo sapiens 133-135 11775254-1 2000 OBJECTIVE: To study in vivo effect of all-trans-retinoic acid (ATRA) or arsenic trioxide (As2O3) on the expression of tissue factor (TF) and the hemostatic disorders, a series of parameters were measured in bone marrow blasts and plasma from acute promyelocytic leukemia (APL) patients. Arsenic Trioxide 90-95 coagulation factor III, tissue factor Homo sapiens 118-131 11775254-1 2000 OBJECTIVE: To study in vivo effect of all-trans-retinoic acid (ATRA) or arsenic trioxide (As2O3) on the expression of tissue factor (TF) and the hemostatic disorders, a series of parameters were measured in bone marrow blasts and plasma from acute promyelocytic leukemia (APL) patients. Arsenic Trioxide 90-95 coagulation factor III, tissue factor Homo sapiens 133-135 11775254-4 2000 RESULTS: The blast cell procoagulant activity (PCA), TF antigen of APL cell lysates, as well as the transcription of APL TF mRNA elevated at diagnosis, were reduced after ATRA or As2O3 therapy. Arsenic Trioxide 179-184 coagulation factor III, tissue factor Homo sapiens 53-55 11775254-7 2000 Both ATRA and As2O3 therapy down-regulated the expression of TF mRNA, decreased the PCA and TF level in APL cells, inhibited coagulation activation, secondary hyperfibrinolysis and recorrected other hemostatic abnormalities, thus greatly improved the bleeding symptom in early stage of the treatment. Arsenic Trioxide 14-19 coagulation factor III, tissue factor Homo sapiens 61-63 11775254-7 2000 Both ATRA and As2O3 therapy down-regulated the expression of TF mRNA, decreased the PCA and TF level in APL cells, inhibited coagulation activation, secondary hyperfibrinolysis and recorrected other hemostatic abnormalities, thus greatly improved the bleeding symptom in early stage of the treatment. Arsenic Trioxide 14-19 coagulation factor III, tissue factor Homo sapiens 92-94 10400422-4 1999 Consistent with the in vivo findings, the membrane PCA, TF antigen and its mRNA level within NB4 cells were rapidly down-regulated by 1 microM ATRA or As2O3, while 0.2 microg/ml DNR increased these TF parameters prior to its effect upon apoptosis induction. Arsenic Trioxide 151-156 coagulation factor III, tissue factor Homo sapiens 56-58 10400422-4 1999 Consistent with the in vivo findings, the membrane PCA, TF antigen and its mRNA level within NB4 cells were rapidly down-regulated by 1 microM ATRA or As2O3, while 0.2 microg/ml DNR increased these TF parameters prior to its effect upon apoptosis induction. Arsenic Trioxide 151-156 coagulation factor III, tissue factor Homo sapiens 198-200 10400422-6 1999 On the other hand, in addition to its modulation on mRNA, As2O3 could also induce an accelerated TF protein turnover. Arsenic Trioxide 58-63 coagulation factor III, tissue factor Homo sapiens 97-99 28343272-0 2017 Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1beta. Arsenic Trioxide 19-22 coagulation factor III, tissue factor Homo sapiens 44-57 17493354-0 2007 [Effects of arsenic trioxide or retinoic acid on mRNA and protein expression of tissue factor and thrombomodulin and procoagulant activity in NB4 cells]. Arsenic Trioxide 12-28 coagulation factor III, tissue factor Homo sapiens 80-93 17493354-1 2007 To investigate the effect of arsenic trioxide (As(2)O(3)) or all-trans retinoic acid (ATRA) on the mRNA and protein expression of tissue factor (TF) and thrombomodulin (TM) and procoagulant activity (PCA) in NB4 cells. Arsenic Trioxide 29-45 coagulation factor III, tissue factor Homo sapiens 130-143 17493354-1 2007 To investigate the effect of arsenic trioxide (As(2)O(3)) or all-trans retinoic acid (ATRA) on the mRNA and protein expression of tissue factor (TF) and thrombomodulin (TM) and procoagulant activity (PCA) in NB4 cells. Arsenic Trioxide 29-45 coagulation factor III, tissue factor Homo sapiens 145-147 17493354-1 2007 To investigate the effect of arsenic trioxide (As(2)O(3)) or all-trans retinoic acid (ATRA) on the mRNA and protein expression of tissue factor (TF) and thrombomodulin (TM) and procoagulant activity (PCA) in NB4 cells. Arsenic Trioxide 47-56 coagulation factor III, tissue factor Homo sapiens 130-143 17493354-1 2007 To investigate the effect of arsenic trioxide (As(2)O(3)) or all-trans retinoic acid (ATRA) on the mRNA and protein expression of tissue factor (TF) and thrombomodulin (TM) and procoagulant activity (PCA) in NB4 cells. Arsenic Trioxide 47-56 coagulation factor III, tissue factor Homo sapiens 145-147 17493354-3 2007 The results showed that 1 micromol/L As(2)O(3) and 1 micromol/L ATRA both gradually downregulated the expression of TF antigen and mRNA on NB4 cells, a human promyelocytic leukemia cell line, in time-dependent manner, as compared with control. Arsenic Trioxide 37-46 coagulation factor III, tissue factor Homo sapiens 116-118 11189487-0 1998 [Tissue factor expression during all-trans retinoic acid or arsenic trioxide treatment in acute promyelocytic leukemia]. Arsenic Trioxide 60-76 coagulation factor III, tissue factor Homo sapiens 1-14 11189487-1 1998 OBJECTIVE: In order to study the effect of all-trans retinoic acid (ATRA) or arsenic trioxide (As2O3) treatment on the expression of tissue factor (TF) in acute promyelocytic leukemia(APL). Arsenic Trioxide 77-93 coagulation factor III, tissue factor Homo sapiens 133-146 11189487-1 1998 OBJECTIVE: In order to study the effect of all-trans retinoic acid (ATRA) or arsenic trioxide (As2O3) treatment on the expression of tissue factor (TF) in acute promyelocytic leukemia(APL). Arsenic Trioxide 77-93 coagulation factor III, tissue factor Homo sapiens 148-150 11189487-1 1998 OBJECTIVE: In order to study the effect of all-trans retinoic acid (ATRA) or arsenic trioxide (As2O3) treatment on the expression of tissue factor (TF) in acute promyelocytic leukemia(APL). Arsenic Trioxide 95-100 coagulation factor III, tissue factor Homo sapiens 133-146 11189487-1 1998 OBJECTIVE: In order to study the effect of all-trans retinoic acid (ATRA) or arsenic trioxide (As2O3) treatment on the expression of tissue factor (TF) in acute promyelocytic leukemia(APL). Arsenic Trioxide 95-100 coagulation factor III, tissue factor Homo sapiens 148-150 11189487-4 1998 CONCLUSION: Both ATRA and As2O3 downregulated the expression of TF mRNA, decreased the PCA and TF levels in APL cells, inhibited coagulation activation and secondary hyperfibrinolysis, thus greatly relieved the bleeding symptom in the early stage of treatment. Arsenic Trioxide 26-31 coagulation factor III, tissue factor Homo sapiens 64-66 11189487-4 1998 CONCLUSION: Both ATRA and As2O3 downregulated the expression of TF mRNA, decreased the PCA and TF levels in APL cells, inhibited coagulation activation and secondary hyperfibrinolysis, thus greatly relieved the bleeding symptom in the early stage of treatment. Arsenic Trioxide 26-31 coagulation factor III, tissue factor Homo sapiens 95-97 28343272-7 2017 In conclusion, although we provide evidence that TNF, IL-1beta, and their signaling intermediates have a regulatory function on TF expression by NB4 APL cells, the effect of ATRA and ATO on TF can only partially be accounted for by their impact on these cytokines. Arsenic Trioxide 183-186 coagulation factor III, tissue factor Homo sapiens 190-192